Biogen (BIIB) Liabilities and Shareholders Equity (2009 - 2026)

Biogen's Liabilities and Shareholders Equity history runs 18 years deep, the most recent figure standing at $29.5 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 5.17% year-over-year to $29.5 billion; the TTM figure through Mar 2026 stood at $116.5 billion (up 4.73% YoY), while the FY2025 annual figure was $29.4 billion, up 4.96% from the prior year.
• Liabilities and Shareholders Equity was $29.5 billion for Q1 2026 at Biogen, roughly flat from $29.4 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $29.5 billion in Q1 2026 to a low of $23.6 billion in Q1 2022.
• Historically, Liabilities and Shareholders Equity has averaged $26.9 billion across 5 years, with a median of $26.8 billion in 2023.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity retreated 1.01% in 2022, then advanced 13.43% in 2023.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $24.6 billion in 2022, then climbed by 9.33% to $26.8 billion in 2023, then rose by 4.49% to $28.0 billion in 2024, then rose by 4.96% to $29.4 billion in 2025, then gained by 0.15% to $29.5 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $29.5 billion (Q1 2026), $29.4 billion (Q4 2025), and $29.2 billion (Q3 2025), per Business Quant data.